Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: a randomized clinical trial
Mao JJ, Xie SX, Keefe JR, Soeller I, Li QS, Amsterdam JD
Published in Phytomedicine
Key Findings
After open-label response, 26 weeks of continued apigenin-standardized chamomile extract did not significantly reduce relapse rate versus placebo, though relapses trended fewer and less severe.
Conclusions
Long-term chamomile was well tolerated but did not significantly prevent GAD relapse.
Limitations
Underpowered for the relapse endpoint; whole extract rather than isolated apigenin.
Supplements Studied
Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: a randomized clinical trial.
Long-term chamomile treatment was well tolerated and reduced anxiety symptoms, but did not significantly prevent relapse of generalized anxiety disorder compared with placebo.
Outcomes Measured
Long-term chamomile treatment was well tolerated and reduced anxiety symptoms, but did not significantly prevent relapse of generalized anxiety disorder compared with placebo.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.